Synergistic inhibition of leukemia WEHI-3 cell growth by arsenic trioxide and Hedyotis diffusa Willd extract in vitro and in vivo

Arsenic trioxide (ATO) is clinically used to treat acute promyelocytic leukemia (APL); however, the therapeutic dose of ATO may prompt critical cardiac side effects. Combination therapy may be used to improve the therapeutic efficiency. To evaluate this possibility, the present study determined the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Yu-Jui, Liu, Yan-Jin, Way, Tzong-Der, Chiang, Su-Yin, Lin, Jaung-Geng, Chung, Jing-Gung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450767/
https://www.ncbi.nlm.nih.gov/pubmed/28587418
http://dx.doi.org/10.3892/etm.2017.4392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450767/
https://www.ncbi.nlm.nih.gov/pubmed/28587418
http://dx.doi.org/10.3892/etm.2017.4392

Ejemplares similares